Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
Status: | Recruiting |
---|---|
Conditions: | Liver Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 80 |
Updated: | 10/15/2017 |
Start Date: | August 2010 |
End Date: | June 2018 |
Contact: | Diane Scavone |
Email: | DScavone@llu.edu |
Phone: | 909-558-3636 |
Randomized Controlled Trial of Proton Beam Radiotherapy + Sorafenib vs. Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared
to Sorafenib alone will produce the best results for treating patients with Hepatocellular
Carcinoma.
to Sorafenib alone will produce the best results for treating patients with Hepatocellular
Carcinoma.
Inclusion Criteria:
1. Patients are candidates to receive both proton beam and sorafenib
2. Patients with tumor burden that exceeds San Francisco criteria
Exclusion Criteria:
1. Patients who are candidates for surgical resection
2. Patients with tumor burden within Milan and/or San Francisco criteria
3. Patients who have contraindication to receive proton
4. Patients with contraindication to receive sorafenib including uncontrolled
hypertension, coumadin treatment and prior intolerability to the drug
5. Patients treated previously by any locoregional treatment
6. Patients with prior liver transplant
7. Patients with child class C
8. Patients with model for end-stage liver disease (MELD) score of > 25
9. Patients with other comorbid diseases that may impact survival
10. Patients with ongoing alcohol intake
11. Patients with active sepsis
12. Patients with gastrointestinal bleeding within a week
13. Patients unwilling to sign informed consent form
14. Patients with history of noncompliance
We found this trial at
1
site
Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...
Click here to add this to my saved trials